Trial NCT01332279

View at ClinicalTrials.gov 
Org. Study IDs: OER-HN-038

Last trial update was posted on 2023-04-04

MeSH Interventions

Erlotinib Hydrochloride Everolimus

MeSH Conditions

Carcinoma Carcinoma, Squamous Cell Carcinoma, Verrucous Head and Neck Neoplasms Laryngeal Diseases Laryngeal Neoplasms Recurrence Salivary Gland Neoplasms Squamous Cell Carcinoma of Head and Neck Tongue Neoplasms

Other Conditions

Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Salivary Gland Cancer Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Verrucous Carcinoma of the Larynx Recurrent Verrucous Carcinoma of the Oral Cavity Salivary Gland Squamous Cell Carcinoma Tongue Cancer

Stopping Reasons

Pharmaceutical co. withdrew support. Study was never activated and did not accrue any patients.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID